课题基金 / 基金详情

项目摘要

项目成果

JANICE B SCHWARTZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Our overall goals are to identify determinants of drug clearance to improve medication therapy for older patients. Algorithms to estimate age, sex, and race effects on renal drug clearance exist. No such algorithms exist for non-renal drug clearance. Because the majority of non-renally cleared medications are metabolized by CYP3A, we began studies with drugs cleared by this enzyme. We have completed the first studies of steady-state CYP-mediated drug clearance in patient populations that include significant numbers of women, the very old (>80 years of age), and residents of assisted living and long-term care facilities. We used the population approach that allows sparse sampling from individuals. To our surprise, clearance rates were among the highest in patients from ages 65-90, and in the oldest nursing home residents. The age-related findings were consistent for three CYP3A substrate drugs that varied widely in pharmacological properties (bioavailabiltiy and transporter affinity). We also found faster clearance in women compared to men and identified covariates (smoking, alcohol intake) that affected clearance in men, but were not present in women, or the oldest patients. Clearance rates also varied by race with whites> blacks and > Hispanics. Dietary analyses suggest vitamin D intake influences CYP3A clearance rates. These results suggest studies of physiologic aging excluding the very old, women, and minority groups may not reflect clearance characteristics in older patients Ithat receive medications. We propose population studies of a CYP3A substrate, atorvastatin, in diverse clinical populations with an interventional study to investigate a potential mechanism for preserved clearance rates in older patients, and the first population studies of CYP2C19- mediated clearance of lansoprazole to investigate age, sex, and genotype (race) effect on steady-state clearance rates of this important polymorphic enzyme. The potential impact of these findings on the care of the growing number of very old patients, especially understudied women and minority groups, is great.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women.
老年人心血管药物使用的性别特异性影响优化老年女性的治疗。
DOI: 10.1097/01.crd.0000078842.86834.93
发表时间: 2003
期刊: Cardiology in review.
影响因子: --
作者: [Schwartz,JaniceB]
通讯作者: Schwartz,JaniceB
Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
患者中缓释维拉帕米的人群分析:性别、种族和吸烟的影响。
DOI: 10.1067/mcp.2003.21
发表时间: 2003
期刊: Clinical pharmacology and therapeutics.
影响因子: --
作者: [Kang,Dongwoo, Verotta,Davide, Krecic-Shepard,MaryEllen, Modi,NishitB, Gupta,SuneelK, Schwartz,JaniceB]
通讯作者: Schwartz,JaniceB
DOI: 10.1001/jamanetworkopen.2022.5491
发表时间: 2022-04-01
期刊: JAMA network open
影响因子: 13.8
作者: [Zimmerman SC, Brenowitz WD, Calmasini C, Ackley SF, Graff RE, Asiimwe SB, Staffaroni AM, Hoffmann TJ, Glymour MM]
通讯作者: Glymour MM
Anticoagulant and thrombolytic therapies in women.
女性的抗凝和溶栓治疗。
DOI: --
发表时间: 2002
期刊: The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.
影响因子: --
作者: [Schwartz,JaniceB]
通讯作者: Schwartz,JaniceB
12
    The study: LatinX/HIspanic Attitudes and Perspectives on Investigations and Studies- of New Drugs: LAPIS-ND
    Optimizing vitamin D in the elderly
    • 批准号:
      8388730
    • 项目类别:
    • 资助金额:
      $22.23万
    • 财政年份:
      2012
    • 负责人:
      JANICE B SCHWARTZ
    • 依托单位:
    Optimizing vitamin D in the elderly
    Optimizing vitamin D in the elderly
    海外基金